← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV14행 · 1개 프로그램
OverviewToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
ADCLimited DatastalePreclinical
disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin plus pyrotinib or naratinib)
RemeGen·Breast Cancer
1 trials
Overview
Program
Disitamab Vedotin plus pyrotinib or naratinib
Overview
Company
RemeGen
Overview
Modality
ADC
Overview
Target
Breast Cancer
Overview
Indication
Breast Cancer
Overview
Phase
PRECLINICAL
Overview
Status
RECRUITING
Overview
Content status
Limited Data
Overview
Data Confidence
Data Confidence · Low
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
Toxicology
Major finding
Long-term remission under Disitamab Vedotin (RC48) in HR-positive/HER2-positive metastatic breast cancer with brain meningeal, and bone marrow involvement: A case report.. Breast cancer (BC) with overexpression of human epidermal growth factor receptor 2 (HER2) is closely associated with an elevated risk of multiple distant metastases and unfavorable prognosis. Disitamab Vedotin (RC48) is a newly …
Clinical
Safety signal
Long-term remission under Disitamab Vedotin (RC48) in HR-positive/HER2-positive metastatic breast cancer with brain meningeal, and bone marrow involvement: A case report.. Breast cancer (BC) with overexpression of human epidermal growth factor receptor 2 (HER2) is closely associated with an elevated risk of multiple distant metastases and unfavorable prognosis. Disitamab Vedotin (RC48) is a newly …
Clinical
Program phase
PRECLINICAL